HomeCompareGRCL vs PM

GRCL vs PM: Dividend Comparison 2026

GRCL yields 19.51% · PM yields 3.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GRCL wins by $21.2K in total portfolio value
10 years
GRCL
GRCL
● Live price
19.51%
Share price
$10.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$70.9K
Annual income
$6,394.90
Full GRCL calculator →
PM
Philip Morris International
● Live price
3.49%
Share price
$164.83
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,502.61
Full PM calculator →

Portfolio growth — GRCL vs PM

📍 GRCL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGRCLPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GRCL + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GRCL pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GRCL
Annual income on $10K today (after 15% tax)
$1,658.54/yr
After 10yr DRIP, annual income (after tax)
$5,435.67/yr
PM
Annual income on $10K today (after 15% tax)
$297.03/yr
After 10yr DRIP, annual income (after tax)
$2,127.22/yr
At 15% tax rate, GRCL beats the other by $3,308.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GRCL + PM for your $10,000?

GRCL: 50%PM: 50%
100% PM50/50100% GRCL
Portfolio after 10yr
$60.3K
Annual income
$4,448.76/yr
Blended yield
7.38%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

GRCL
Analyst Ratings
3
Buy
5
Hold
Consensus: Hold
Price Target
$6.00
-41.5% upside vs current
Range: $6.00 — $6.00
Altman Z
1.5
Piotroski
3/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.9% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GRCL buys
0
PM buys
0
No recent congressional trades found for GRCL or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGRCLPM
Forward yield19.51%3.49%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$70.9K$49.6K
Annual income after 10y$6,394.90$2,502.61
Total dividends collected$39.8K$11.8K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy
Analyst price target$6.00$194.30

Year-by-year: GRCL vs PM ($10,000, DRIP)

YearGRCL PortfolioGRCL Income/yrPM PortfolioPM Income/yrGap
1← crossover$12,651$1,951.22$11,650$409.56+$1.0KGRCL
2$15,844$2,307.04$13,592$497.49+$2.3KGRCL
3$19,653$2,700.22$15,882$605.21+$3.8KGRCL
4$24,159$3,130.30$18,589$737.41+$5.6KGRCL
5$29,447$3,596.27$21,794$899.94+$7.7KGRCL
6$35,604$4,096.58$25,597$1,100.16+$10.0KGRCL
7$42,726$4,629.21$30,118$1,347.30+$12.6KGRCL
8$50,908$5,191.72$35,505$1,652.97+$15.4KGRCL
9$60,253$5,781.31$41,940$2,031.88+$18.3KGRCL
10$70,866$6,394.90$49,643$2,502.61+$21.2KGRCL

GRCL vs PM: Complete Analysis 2026

GRCLStock

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.

Full GRCL Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this GRCL vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GRCL vs SCHDGRCL vs JEPIGRCL vs OGRCL vs KOGRCL vs MAINGRCL vs MOGRCL vs BTIGRCL vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.